Search
INSPIRE trial
International randomized trial toptropium compared with salmeterol/fluticasone (Advair) supported by the manufacturer of Advair
1323 patients with severe COPD, 2 year study
inhaled salmeterol/fluticasone 50/500 ug BID vs
inhaled tiotropium 18 ug QD + inhaled placebo QD
Primary endpoint:
- exacerbations that required antibiotics, systemic steroids or hospitalization
Results:
- more patients in the tiopropium group withdrew
- primary endpoint similar in both groups
- questionnaires about health & well-being slightly better in salmeterol/fluticasone group
- higher rate of pneumonia in salmeterol/fluticasone group 8% vs 4 %
- mortality lower in salmeterol/fluticasone group 3% vs 6%
General
clinical trial
References
- Wedzicha JA et al,
The prevention of chronic obstructive pulmonary disease
exacerbations by salmeterol/fluticasone propionate or
tiotropium bromide.
Am J Respir Crit Care Med 2008, 177:19
PMID: 17916806